# ENV-501

Source: https://onco.cc/drugs/env-501/  
OnCo record `env-501` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ENV-501 is an experimental antibody-drug conjugate from Hummingbird Bioscience in phase 2 trials for melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, aimed at HER3.

## Summary

ENV-501 is an antibody-drug conjugate developed by Hummingbird Bioscience. Its target is HER3. ClinicalTrials.gov describes the intervention as: ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06956690, plans to enrol 180 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Antibody-drug conjugate directed at HER3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of ENV-501: https://clinicaltrials.gov/search?intr=ENV-501

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [HER3](https://onco.cc/targets/her3/)
- trials: [A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ](https://onco.cc/trials/nct06956690/)

---
JSON: https://onco.cc/api/v1/entities/env-501.json